Market research
SAVA Cassava Sciences Inc
Current ticker: SAVA
NASDAQ USD Healthcare
Latest close
As of 10 Jun 2026
Test a moving-average rule with historical data.
Market facts
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -0.84
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -0.84
About
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Research context
Cassava Sciences Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SAVA discussion.
5 years, 6 months ago
Cassava Sciences, Inc is currently in a long term uptrend where the price is trading 199.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cassava Sciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 317.8% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 508.2% to $-4M since the same quarter in the previous year.
Based on the above factors, Cassava Sciences, Inc gets an overall score of 2/5.